RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...

The investors in Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) will be rubbing their hands together with glee today, after the share price leapt 21% to US$12.04 in the week following its quarterly ...

Clinical-stage biotechnology firm Recursion announced the release of an open-source biological dataset, RxRx1, which the company has been building for more than five years. The dataset is composed of ...

Recursion Pharma is an AI-driven drug developer that boasts supercomputers designed to shorten drug development timelines and enhance successful outcomes. Many such companies have raised substantial ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a Fast Company “Most Innovative Company” and leader in the artificial intelligence for drug discovery movement, today announced it will open-source a ...